🔎 Trials Near Me

Acasă › Cancer pulmonar cu celule non-pătrate › New Hampshire

Studii clinice pentru Cancer pulmonar cu celule non-pătrate în New Hampshire

17 studii pentru Cancer pulmonar cu celule non-pătrate caută participanți în New Hampshire.

Orașe în New Hampshire

Text oficial al studiului (în engleză)

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

  • Dartmouth-Hitchcock Medical Center /ID# 277673, Lebanon
În curs de recrutareFaza 2/3
Vârste de 18 ani și peste · Toate sexele · Actualizat 5 oct. 2026 · NCT07155187

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

  • New Hampshire Oncology Hematology PA-Concord, Concord
  • Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon
  • Solinsky Center for Cancer Care, Manchester
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Toate sexele · Actualizat 5 oct. 2026 · NCT04267848

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

  • Dartmouth-Hitchcock Medical Center, Lebanon
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Toate sexele · Actualizat 29 sept. 2026 · NCT06881784

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

  • Dartmouth Hitchcock Medical Center, Lebanon
În curs de recrutareFaza 2
Vârste de 18 ani și peste · Toate sexele · Actualizat 25 sept. 2026 · NCT06667076

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

  • Dartmouth-Hitchcock Medical Center, Lebanon
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Toate sexele · Actualizat 24 sept. 2026 · NCT06890598

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

  • Clinical Study Site, Lebanon
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Toate sexele · Actualizat 18 sept. 2026 · NCT06767514

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

  • Dartmouth Hitchcock Medical Center, Lebanon
În curs de recrutareFaza 2
Vârste de 18 ani și peste · Toate sexele · Actualizat 10 sept. 2026 · NCT04302025

A Phase 1/1b Study of IAM1363 in HER2 Cancers

  • Dartmouth Hitchcock Medical, Lebanon
În curs de recrutareFaza 1
Vârste de 18 ani și peste · Toate sexele · Actualizat 9 sept. 2026 · NCT06253871

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

  • Dartmouth-Hitchcock Medical Center, Lebanon
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Toate sexele · Actualizat 8 sept. 2026 · NCT06119581

KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

  • Dartmouth Hitchcock Medical Center ( Site 0016), Lebanon
În curs de recrutareStudiu observațional
Vârste de 18 ani și peste · Toate sexele · Actualizat 25 aug. 2026 · NCT04165798

KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

  • Dartmouth Hitchcock Medical Center ( Site 0016), Lebanon
În curs de recrutareFaza 1/2
Vârste de 18 ani și peste · Toate sexele · Actualizat 25 aug. 2026 · NCT04165070

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

  • New Hampshire Oncology Hematology PA-Concord, Concord
  • Solinsky Center for Cancer Care, Manchester
În curs de recrutareFaza 2
Vârste de 18 ani și peste · Toate sexele · Actualizat 3 iun. 2026 · NCT05642572

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

  • New Hampshire Oncology Hematology PA-Concord, Concord
  • Solinsky Center for Cancer Care, Manchester
În curs de recrutareFaza 2
Vârste de 18 ani și peste · Toate sexele · Actualizat 6 mai 2026 · NCT06116682

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

  • New Hampshire Oncology Hematology PA-Concord, Concord
  • Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon
  • Solinsky Center for Cancer Care, Manchester
În curs de recrutareFaza 2/3
Vârste de 18 ani și peste · Toate sexele · Actualizat 5 mai 2026 · NCT06616584

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

  • New Hampshire Oncology Hematology PA-Concord, Concord
  • Solinsky Center for Cancer Care, Manchester
În curs de recrutareFaza 2
18 Minutes · Toate sexele · Actualizat 5 mai 2026 · NCT06031688

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

  • Dartmouth Hitchcock, Lebanon
În curs de recrutareFaza 1/2
Vârste de 18 ani și peste · Toate sexele · Actualizat 13 apr. 2026 · NCT06362369

A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors

  • Dartmouth Hitchcock Medical Center, Lebanon
În curs de recrutareFaza 1
Vârste de 18 ani și peste · Toate sexele · Actualizat 20 mar. 2026 · NCT05948865

Sursă: ClinicalTrials.gov, date preluate la 6 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.